BioNTech’s net profit falls sharply

BioNTech announced its balance sheet for the January-March period.

Consequently, the company’s net profit in the first quarter of this year decreased by 86 percent compared to the same period last year, to 502.2 million euros.

BioNTech announced a profit of 3.7 billion euros in the first quarter of 2022.

The company’s net profit per share, which was 14.24 euros in the first quarter of last year, fell to 2.05 euros in the same period this year.

BioNTech’s revenue, on the other hand, was down 80% in the first quarter of this year compared to the same period last year, to €1.3bn.

The company had revenue of 6.4 billion euros in the first quarter of 2022.

LOW INCOME FROM VACCINE SALES

In the statement made by the company, it was indicated that the variation in financial results was due to the company’s lower income from the supply and sale of vaccines against Covid-19 worldwide.

It was noted that revenue from Covid-19 vaccines is projected to be approximately €5 billion in 2023.

The World Health Organization (WHO) announced on May 5 that Covid-19 had ended as a “public health emergency” of international concern. (AA)